The first drug for imaging prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer was approved by the US Food and Drug Administration on 1 December. It is designed to be used with positron emission tomography (PET). The drug, Gallium 68 PSMA-11, is indicated for patients with suspected prostate cancer metastasis who are potentially curable by surgery or radiation therapy. It is also indicated for patients with suspected prostate cancer recurrence based on elevated prostate-specific antigen (PSA) levels.
